Patient Access to MRI Scans Expanded with CE Marking Approval for Pacemaker Leads
By MedImaging International staff writers Posted on 08 Oct 2014 |
Image: St. Jude Medical announced CE marking approval of updated labeling for its Tendril STS and IsoFlex Optim pacemaker leads (Photo courtesy of St. Jude Medical).
New pacemaker leads have received CE marking approval, allowing existing and future patients with the devices access to magnetic resonance imaging (MRI) scans in Europe.
St. Jude Medical, Inc. (St. Paul, Minnesota, USA), a global medical device company, has announced CE marking approval of updated labeling for its Tendril STS and IsoFlex Optim. The leads are used with the Accent MRI pacemaker, an advanced pacing platform that provides the added benefit of MRI scanning capability.
“St. Jude Medical is committed to providing MRI-compatible pacing solutions to patients and physicians around the world,” said Eric S. Fain, MD, group president of St. Jude Medical. “We believe many patients can benefit from pacing therapies with MRI scanning capabilities when they have additional health concerns. We are dedicated to the development of existing and future heart rhythm technologies that are compatible with this important diagnostic tool.”
Yearly, approximately one million pacemakers are implanted worldwide. The Tendril STS and IsoFlex Optim pacing leads are built on the Tendril and IsoFlex lead platforms, and include the company’s exclusive Optim insulation material. Optim insulation is a hybrid insulation material that blends the biostability and flexibility of high-performance silicone rubber with the strength, tear resistance and abrasion resistance of polyurethane. This combination is designed to provide increased durability, and to improve flexibility, handling characteristics and control during implant procedures. The updated labeling further demonstrates the safety of the Tendril STS and IsoFlex Optim pacing leads, which were originally designed to be used in an MRI setting. In actively monitored registries, the Tendril STS and IsoFlex Optim pacing leads have demonstrated effectiveness with over 99% survivability in patients.
St. Jude Medical reported, in addition to this approval, that it plans to seek updated labeling for many existing products to allow patients the ability to safely undergo MRI scans. St. Jude Medical plans to submit testing data in key markets worldwide such as Europe, Japan, Australia, and the United States for MRI conditional labeling on several additional existing products including the Fortify Assura implantable cardioverter defibrillator (ICD), Ellipse ICD, Quadra Assura cardiac resynchronization therapy defibrillator (CRT-D), Durata and Optisure defibrillation leads.
Related Links:
St. Jude Medical
St. Jude Medical, Inc. (St. Paul, Minnesota, USA), a global medical device company, has announced CE marking approval of updated labeling for its Tendril STS and IsoFlex Optim. The leads are used with the Accent MRI pacemaker, an advanced pacing platform that provides the added benefit of MRI scanning capability.
“St. Jude Medical is committed to providing MRI-compatible pacing solutions to patients and physicians around the world,” said Eric S. Fain, MD, group president of St. Jude Medical. “We believe many patients can benefit from pacing therapies with MRI scanning capabilities when they have additional health concerns. We are dedicated to the development of existing and future heart rhythm technologies that are compatible with this important diagnostic tool.”
Yearly, approximately one million pacemakers are implanted worldwide. The Tendril STS and IsoFlex Optim pacing leads are built on the Tendril and IsoFlex lead platforms, and include the company’s exclusive Optim insulation material. Optim insulation is a hybrid insulation material that blends the biostability and flexibility of high-performance silicone rubber with the strength, tear resistance and abrasion resistance of polyurethane. This combination is designed to provide increased durability, and to improve flexibility, handling characteristics and control during implant procedures. The updated labeling further demonstrates the safety of the Tendril STS and IsoFlex Optim pacing leads, which were originally designed to be used in an MRI setting. In actively monitored registries, the Tendril STS and IsoFlex Optim pacing leads have demonstrated effectiveness with over 99% survivability in patients.
St. Jude Medical reported, in addition to this approval, that it plans to seek updated labeling for many existing products to allow patients the ability to safely undergo MRI scans. St. Jude Medical plans to submit testing data in key markets worldwide such as Europe, Japan, Australia, and the United States for MRI conditional labeling on several additional existing products including the Fortify Assura implantable cardioverter defibrillator (ICD), Ellipse ICD, Quadra Assura cardiac resynchronization therapy defibrillator (CRT-D), Durata and Optisure defibrillation leads.
Related Links:
St. Jude Medical
Latest MRI News
- Low-Cost Whole-Body MRI Device Combined with AI Generates High-Quality Results
- World's First Whole-Body Ultra-High Field MRI Officially Comes To Market
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer